BioLife Solutions (NASDAQ:BLFS) Given New $27.00 Price Target at HC Wainwright

BioLife Solutions (NASDAQ:BLFS) had its target price decreased by HC Wainwright from $29.00 to $27.00 in a research report report published on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the medical equipment provider’s stock.

Several other equities research analysts also recently weighed in on BLFS. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, TD Cowen lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and a consensus target price of $27.50.

BioLife Solutions Trading Down 2.6 %

Shares of BLFS stock opened at $20.47 on Monday. The stock’s fifty day moving average price is $23.94 and its two-hundred day moving average price is $22.84. The company has a market cap of $949.60 million, a PE ratio of -19.31 and a beta of 1.88. BioLife Solutions has a fifty-two week low of $11.91 and a fifty-two week high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.81 and a current ratio of 2.78.

Insider Activity at BioLife Solutions

In related news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at $7,593,412.40. The trade was a 3.05 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares of the company’s stock, valued at $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,471 shares of company stock valued at $656,330 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares during the last quarter. Barclays PLC raised its holdings in BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after acquiring an additional 10,803 shares during the period. State Street Corp raised its holdings in BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the period. Stifel Financial Corp increased its holdings in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the period. Finally, Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the third quarter worth $28,000. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.